Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 1;11(2):567–578. doi: 10.7150/thno.48620

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Pre-therapeutic [⁶⁸Ga]Pentixafor-PET/MRI and [¹⁸F]FDG-PET/MRI of an 82-year-old female MCL patient. [⁶⁸Ga]Pentixafor-PET detects considerably more nodal lymphoma manifestations than [¹⁸F]FDG-PET, and stronger tracer uptake in several lesions/regions. All lymph nodes with focal increased [⁶⁸Ga]Pentixafor uptake corresponded to clearly enlarged lymph nodes on diffusion-weighted MRI (DWI). Representative examples of such [⁶⁸Ga]Pentixafor-PET-positive lesions with no or low [¹⁸F]FDG uptake, but obvious lymphadenopathy on DWI, are marked by blue arrowheads (left axially, retroperitoneal/periaortic, and right pelvic regions).